Matching Geography

Reports matching your search in:
 
 

Research Assistance

 

Free Alert Me service

Receive bi-weekly email alerts on new market research

Sign Up Today!
 

Vaccines

1594

A vaccine is a preparation used to prevent contraction of a particular disease by triggering an immune response to that disease. Because of the large number of deadly diseases that have been eliminated through the proliferation of effective vaccines, vaccination is generally viewed as one of the greatest public health achievements during the 20th century. However, risks are associated with using all immunobiologics, and no vaccine is 100% safe or effective.

Key issues in the global vaccine market today include product safety, supply shortages, the use of vaccines to prevent pandemics and address bioterrorism, and innovations in vaccine delivery systems.

The topic of vaccine safety became prominent during the mid 1970’s with increases in lawsuits filed on behalf of those presumably injured by the diphtheria, pertussis, and tetanus (DPT) vaccine. To respond to public health concerns, Congress passed the National Childhood Vaccine Injury Act (NCVIA) in 1986, which in turn led to the creation of the National Vaccine Program Office (NVPO) within the Department of Health and Human Services (DHHS). NCVIA requires that all healthcare providers who administer vaccines containing diphtheria, tetanus, pertussis, polio, measles, mumps, rubella, hepatitis B, Haemophilus influenzae type b and varicella provide a Vaccine Information Statement (VIS) to the vaccine recipient, their parent or legal guardian prior to each dose. Each VIS contains a brief description of the disease as well as the risks and benefits of the vaccine. The NCVIA also mandated that all healthcare providers report certain adverse events that occur following vaccination. As a result, the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink Project (VSD) were established in 1990. VAERS provides a mechanism for the collection and analysis of adverse events associated with vaccines currently licensed in the U.S.; VSD involved forming partnerships with four large health maintenance organizations (HMOs) to continually monitor vaccine safety. The National Vaccine Injury Compensation Program, which was also created by NCVIA, compensates those individuals who have been injured by vaccines on a no-fault basis. On a global basis, the World Health Organization (WHO) is actively involved in ensuring the quality of vaccines.

RSS Feeds

All reports in Vaccines

< prev 1  2  3  4  5  6  7  8  9  10  next >
Triple Analysis: Angiogenesis, Cancer Vaccines and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
... pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas. Below is ...  |  more...
$5,175.00
Triple Analysis: Cancer Vaccines, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
... evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer ...  |  more...
$5,175.00
Triple Analysis: Cancer Vaccines, Protein Kinase Inhibitors and Peptides
5/1/2012 | published by: BioSeeker Group AB
... evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer ...  |  more...
$5,175.00
Triple Analysis: Colorectal Cancer, Cancer Vaccines and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
... standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but ...  |  more...
$5,175.00
Triple Analysis: Melanoma, Cancer Vaccines and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
... criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also ...  |  more...
$5,175.00
Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
... standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but ...  |  more...
$5,175.00
Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
... standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but ...  |  more...
$5,175.00
Triple Analysis: Apoptosis, Cancer Vaccines and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
... pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas. Below is ...  |  more...
$5,175.00
Triple Analysis: Breast Cancer, Cancer Vaccines and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
... standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but ...  |  more...
$5,175.00
Triple Analysis: Leukemia, Cancer Vaccines and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
... criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also ...  |  more...
$5,175.00
Triple Analysis: Lung Cancer, Cancer Vaccines and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
... standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but ...  |  more...
$5,175.00
Triple Analysis: Lymphoma, Cancer Vaccines and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
... criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also ...  |  more...
$5,175.00
Research Report on Chinese Bio-pharmaceutical Industry, 2012
3/21/2012 | published by: China Research and Intelligence Co., Ltd.
... bio-pharmaceutical industry. "Bio-pharmaceutical" in the report only refers to human biological products. Chinese biological product industry is an emerging industry which has only over 20 years of history. In 2011, the sales revenue of Chinese ...  |  more...
$3,000.00
Pediatric Vaccines Market to 2017- Strategic Focus on Partnering as Licensing and Co-Development Accounted for 69% of Deal-Making Activity from 2004-2011
3/14/2012 | published by: GBI Research
... Vaccines Market to 2017- Strategic Focus on Partnering as Licensing and Co-Development Accounted for 69% of Deal-Making Activity from 2004-2011”, which provides insights into global pediatric vaccines market forecast until 2017. The report provides an ...  |  more...
$3,500.00
Research Report on Chinese Human Vaccine Industry, 2012
3/7/2012 | published by: China Research and Intelligence Co., Ltd.
... than that of the treatment. Hence, it is of significance to make great contribution to save social resources. In China, vaccine is customarily divided into vaccine I and Vaccine II. Vaccine I is offered for ...  |  more...
$3,000.00
Cancer Vaccine Partnering Agreements
3/1/2012 | published by: Current Partnering
... how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These ...  |  more...
$1,695.00
Triple Analysis: Pancreatic Cancer, Apoptosis and Cancer Vaccines
3/1/2012 | published by: BioSeeker Group AB
... in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between ...  |  more...
$5,175.00
Triple Analysis: Lymphoma, Pancreatic Cancer and Cancer Vaccines
3/1/2012 | published by: BioSeeker Group AB
... a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different ...  |  more...
$5,175.00
Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Protein Kinase Inhibitors
3/1/2012 | published by: BioSeeker Group AB
... standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but ...  |  more...
$5,175.00
Triple Analysis: Leukemia, Pancreatic Cancer and Cancer Vaccines
3/1/2012 | published by: BioSeeker Group AB
... a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different ...  |  more...
$5,175.00
Triple Analysis: Lung Cancer, Pancreatic Cancer and Cancer Vaccines
3/1/2012 | published by: BioSeeker Group AB
... in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between ...  |  more...
$5,175.00
Triple Analysis: Melanoma, Pancreatic Cancer and Cancer Vaccines
3/1/2012 | published by: BioSeeker Group AB
... a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different ...  |  more...
$5,175.00
Triple Analysis: Pancreatic Cancer, Prostate Cancer and Cancer Vaccines
3/1/2012 | published by: BioSeeker Group AB
... in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between ...  |  more...
$5,175.00
Human Vaccines
3/1/2012 | published by: Global Industry Analysts
... Japan, Europe, Asia-Pacific, Middle East and Latin America. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report also analyzes the ...  |  more...
$4,500.00
Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Cancer Vaccines
3/1/2012 | published by: BioSeeker Group AB
... in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between ...  |  more...
$5,175.00
< prev 1  2  3  4  5  6  7  8  9  10  next >